截至10月28日，禾元生物股东户数4.71万，较上期增加84075.00%；人均流通股869股，较上期减少 99.85%。2025年1月-9月，禾元生物实现营业收入1966.08万元，同比减少8.51%；归母净利润-1.21亿 元，同比减少8.44%。 责任编辑：小浪快报 融券方面，禾元生物1月27日融券偿还0.00股，融券卖出0.00股，按当日收盘价计算，卖出金额0.00元； 融券余量0.00股，融券余额0.00元。 资料显示，武汉禾元生物科技股份有限公司位于湖北省武汉市武汉东湖新技术开发区神墩五路268号， 成立日期2006年11月16日，上市日期2025年10月28日，公司主营业务涉及运用水稻胚乳细胞重组蛋白表 达技术平台进行植物源人血清白蛋白等产品的研发、生产及销售。主营业务收入构成为：重组人白蛋白 75.44%，其他24.56%。 1月27日，禾元生物涨0.85%，成交额2.17亿元。两融数据显示，当日禾元生物获融资买入额1611.76万 元，融资偿还2512.54万元，融资净买入-900.78万元。截至1月27日，禾元生物融资融券余额合计2.62亿 元。 融资方面，禾元生物当日融资买入1611.7 ...

截至发稿，赵栩累计任职时间14年106天，现任基金资产总规模688.85亿元，任职期间最佳基金回报 233.59%， 任职期间最差基金回报-84.87%。 声明：市场有风险，投资需谨慎。 本文基于第三方数据库自动发布，任何在本文出现的信息（包括但 不限于个股、评论、预测、图表、指标、理论、任何形式的表述等）均只作为参考，不构成个人投资建 议。受限于第三方数据库质量等问题，我们无法对数据的真实性及完整性进行分辨或核验，因此本文内 容可能出现不准确、不完整、误导性的内容或信息，具体以公司公告为准。如有疑问，请联系 biz@staff.sina.com.cn。 责任编辑：小浪快报 数据显示，工银瑞信基金旗下1只基金重仓禾元生物。工银科创ETF联接A（011614）四季度持有股数 1.65万股，占基金净值比例为0.02%，位居第五大重仓股。根据测算，今日浮盈赚取约1.15万元。连续3 天上涨期间浮盈赚取8.43万元。 工银科创ETF联接A（011614）成立日期2021年3月5日，最新规模14.94亿。今年以来收益13.15%，同类 排名53/335；近一年收益54.14%，同类排名42/209；成立以来收益19.7 ...

证券日报网讯1月23日，禾元生物在互动平台回答投资者提问时表示，截至目前，公司药用水稻种植面 积已超过9000亩，公司将根据现有产能和拟建设产线的产能需求分步规划落实，逐步扩大种植用地，保 障原料种植与产能相匹配。目前120吨重组人白蛋白生产线主体结构已完成施工建设，部分设备已完成 调试，部分设备处于陆续进场调试阶段。 ...

（编辑 王雪儿） 证券日报网讯 1月21日，贝达药业在互动平台回答投资者提问时表示，公司与武汉禾元生物科技股份有 限公司已达成重组人白蛋白注射液（水稻）的商业化区域合作，作为突破性的重组人白蛋白产品，其临 床研究疗效不劣于人血浆白蛋白，且克服了血源安全风险，目前相关的市场推广和销售工作正在加紧推 进当中。公司持有禾元生物5.6%股份，目前尚在锁定期，锁定时间为上市后一年。 ...

Group 1 - The company, BeiGene, stated that its investment in Wuhan Heyuan Biotechnology Co., Ltd. is accounted for under other equity instruments, and the fair value changes are recorded in other comprehensive income, which does not affect the company's net profit [1]

Group 1 - The company, Betta Pharmaceuticals (300558.SZ), announced a commercial cooperation with Wuhan Heyuan Biotechnology Co., Ltd. for the regional commercialization of recombinant human albumin injection (rice-based) [1] - The recombinant human albumin product is considered breakthrough, with clinical research showing efficacy comparable to human plasma albumin while overcoming safety risks associated with blood sources [1] - The company holds a 5.6% stake in Heyuan Biotechnology, which is currently under a lock-up period lasting one year post-IPO [1]

Core Viewpoint - He Yuan Bio stated that it cannot disclose specific information regarding product sales, market feedback, new drug approval progress, medical insurance access plans, and 2025 annual report performance due to the sensitive nature of this information [1] Group 1 - The company emphasized that disclosing such information prematurely or in a non-standard manner could violate the principle of information disclosure fairness and potentially impact the trading order of the securities market [1] - He Yuan Bio plans to enhance communication with investors through regular reports and performance briefings to address reasonable concerns [1]

Core Insights - In 2025, Hubei province achieved a record high with 4 new Class I innovative drugs and 3 Class III innovative medical devices approved for market, with Wuhan contributing 3 of the Class I drugs [1][2] Group 1: Innovative Drug Developments - Hubei's new Class I innovative drugs include two significant products from local companies: He Yuan Bio (688765.SH) and Jianmin Pharmaceutical (600976.SH) [1][2] - He Yuan Bio's recombinant human albumin injection (rice-based) is the first approved recombinant human serum albumin product in China, addressing the issue of reliance on imported albumin [2][5] - Jianmin Pharmaceutical's pediatric heat-reducing patch is the only approved traditional Chinese medicine gel patch for children in the last 20 years, filling a market gap for pediatric external treatments [3] Group 2: Policy Support and Industry Ecosystem - Hubei's innovative achievements are supported by a robust industrial ecosystem, with over 3,000 biopharmaceutical companies in the Optics Valley Biotech City, creating a comprehensive industry chain from R&D to production [4] - The Hubei provincial government aims to double the biopharmaceutical industry's revenue to 250 billion yuan by 2027, with specific targets for companies exceeding 500 million yuan, 100 million yuan, and 50 million yuan in revenue [4] - The provincial drug regulatory authority has implemented measures to enhance the approval process for innovative products, significantly boosting the vitality of the pharmaceutical industry [4][5]

Group 1 - The core viewpoint of the news is that He Yuan Bio has shown a significant increase in stock price and trading activity, indicating positive market sentiment towards the company [1] - As of January 13, He Yuan Bio's stock price rose by 2.03% to 79.57 CNY per share, with a total market capitalization of 28.446 billion CNY [1] - The company has experienced a year-to-date stock price increase of 15.14%, with a 10.09% rise over the last five trading days and a 2.62% increase over the last 20 days [1] Group 2 - He Yuan Bio's main business involves the research, production, and sales of products using rice endosperm cell recombinant protein expression technology, with recombinant human albumin accounting for 75.44% of its revenue [1] - As of October 28, the number of shareholders for He Yuan Bio reached 47,100, a significant increase of 84,075% compared to the previous period [2] - For the period from January to September 2025, He Yuan Bio reported operating revenue of 19.6608 million CNY, a year-on-year decrease of 8.51%, and a net profit attributable to shareholders of -121 million CNY, also a decrease of 8.44% year-on-year [2]

Core Viewpoint - The company emphasizes the importance of investor relations management and ensures that all communications with investors are based on legally disclosed information, avoiding any misleading statements [2] Group 1 - The company stated that it does not have any undisclosed information that should be disclosed [2] - The company commits to timely announcements if any significant events occur that meet disclosure standards [2]